Cancer researchers announced a new international clinical trial on Friday to test whether continuous digital monitoring can help doctors catch toxicities earlier in advanced breast cancer.
Spearheaded from Spain by Solti, alongside French partner Unicancer and German collaborator WSG, the academic research unveiled a framework at ESMO AI & Digital Oncology 2026 combining digital technologies to track physiological shifts and symptoms in the intervals between clinical appointments.
The TOP-REAL trial is an open-label, single-arm, non-randomized, multicenter phase 2 study assessing the efficacy and safety of first-line treatment with trastuzumab deruxtecan (T-DXd) plus pertuzumab in approximately 300 patients across 60 centers in Spain, France, and Germany, according to Solti. The study is already active in all three participating countries, with patients on study in Spain and France and recruitment open in Germany.
Eligible participants include male or pre- and post-menopausal women aged 18 years or older with locally advanced or metastatic HER2-positive breast cancer who have not received prior chemotherapy or HER2-targeted therapy for advanced or metastatic disease, per Veeva.
Patients will receive T-DXd at 5.4 mg/kg administered as an intravenous infusion every three weeks, combined with pertuzumab at a loading dose of 840 mg on Day 1 of Cycle 1, followed by 420 mg in subsequent cycles every three weeks.
“We want patients not only to benefit from advances that allow better control of their disease, but also to live better during treatment. Ultimately, TOP-REAL was conceived with a dual ambition: to improve clinical outcomes and place patients’ quality of life at the center of care.”
explained Dr. Cristina Saura, who serves as the lead investigator for TOP-REAL, sits on the Solti Board, and directs both the Breast Cancer Unit at Vall d’Hebron University Hospital and the Breast Cancer Group at VHIO.
The study incorporates a mobile app—either CANKADO or Resilience, depending on the country and site—accessed through the patient’s phone to provide remote or automated patient monitoring through electronic patient-reported outcomes, educational content, and optional self-management programs such as cognitive behavioral therapy for fatigue, adapted physical activity, and meditation via Resilience.
Participants are also equipped with a pulse oximeter for self-tracking oxygen saturation and heart rate, and a smartwatch to collect granular physiological data.
“Precisely because treatments are becoming increasingly effective and allow patients to live longer, we need to pay growing attention to how they live during that time,” added Dr. Saura.
Among the specific toxicities evaluated is interstitial lung disease or pneumonitis associated with T-DXd, with daily oxygen saturation measurements and periodic exercise tests exploring whether certain changes support earlier medical assessment. Tumor assessments will take place every 9 weeks for the first 12 months, and every 12 weeks thereafter until disease progression or study completion.
Keep reading